During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.
Potential adalimumab biosimilar demonstrates similar safety and immunogenicity to reference
In a multicenter, double-blind, parallel-group, 52-week phase 3 study,1 researchers compared the safety and efficacy of Fresenius Kabi’s proposed adalimumab biosimilar, MSB11022, with the originator product in patients with moderate-to-severe chronic plaque psoriasis.
The study included 443 patients from 69 sites that spanned 12 countries. Participants were randomized to receive either MSB11022 (n = 202) or the reference adalimumab (n = 189) at a dose of 80 mg subcutaneously on day 1, and 40 mg every other week from weeks 2 to 14. The primary endpoint of the study was Psoriasis Area and Severity Index (PASI) 75 at week 16.
Researchers presented interim results of the trial’s progression at 16 weeks during the conference. The study demonstrated that 89.6% of MSB11022 patients reached PASI 75, versus 91.5% of patients taking the originator product. The immunogenicity profiles were comparable.
Study finds trial dropouts do not affect determinations of clinical similarity
Amgen’s ABP 501, an EMA- and FDA-approved adalimumab biosimilar, was recently studied2 in a tipping point sensitivity analysis compared with reference adalimumab in the treatment of rheumatoid arthritis.
The study authors noted that patient withdrawals from trials can often lead to incomplete data collection and subsequent loss of statistical power of the trial. The goal of this study was to examine the potential effects of missing data and determine how sensitive the results are.
The primary endpoint of the study was measured by the American College of Rheumatology’s 20% improvement criteria (ACR20) at week 24. Among participants who completed the study, the ACR20 response rate was 77% for the biosimilar adalimumab group and 74.7% for the reference adalimumab group.
Researchers found that, overall, the tipping point sensitivity analyses demonstrated that the effects of missing data due to study dropouts would not change the overall conclusion of clinical similarity between the reference and the biosimilar products.
References
1. Hercogova J, Papp KA, Edwards CJ, et al. A randomized, double-blind trial comparing the efficacy, safety and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB0954. doi: 10.1136/annrheumdis-2018-eular.5146.
2. Zhang N, Wang H, Krishnan E. Clinical equivalence in efficacy between ABP 501 and adalimumab in patients with moderate to severe rheumatoid arthritis: a tipping point analysis. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB0457. doi: 10.1136/annrheumdis-2018-eular.6855.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.